How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter. During the same quarter in the prior year, the company posted ($0.10) EPS.

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN) , Gilead Sciences (gild) , OPKO Health (OPK) , Sangamo Therapeutics (SGMO) , Ionis Pharmaceuticals (IONS) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) , Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU) .

NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ZIOP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.82
▼
$1.39
52-Week Range: N/A

Volume: 2.13 million shs
Average Volume: 2.01 million shs
Market Capitalization: $187.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get ZIOPHARM Oncology alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

ZIOP Stock News Headlines

February 10, 2024 | investing.com

Alx Oncology Holdings (ALXO)

January 31, 2024 | reuters.com

CG Oncology Inc

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 18, 2023 | markets.businessinsider.com

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?

September 15, 2023 | newsweek.com

WBSPH 2024 - Oncology

August 29, 2023 | thestreet.com

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

June 21, 2023 | investing.com

Ziopharm’s palifosfamide fails in first-line STS…

June 15, 2023 | morningstar.com

ALX Oncology Holdings Inc Ordinary Shares

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

June 9, 2023 | finance.yahoo.com

Intratumoral Cancer Therapies Global Market Report 2023

May 11, 2023 | marketwatch.com

Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co

March 27, 2023 | marketwatch.com

Global Drugs for Non-small Cell Lung Cancer Market Size 2023 to 2026 Size and Share Survey Report

March 27, 2023 | marketwatch.com

Chronic Lymphocytic Leukemia Market 2023 Size and Forecast to 2030

February 23, 2023 | finance.yahoo.com

USA Community Oncology Services Market Competitor Scenario - Market Positioning And Player-Based Strategies, By The Business Research Company

February 18, 2023 | finance.yahoo.com

Verdi Oncology's Horizon Oncology Announces Agreement with Integra Connect to Bring Value-Based Care to Central Indiana

February 18, 2023 | marketwatch.com

Global Gene Therapy in Oncology Market Size is Booming Across the Globe and Witness Huge Growth by Key Players to 2030 By VMReports

February 18, 2023 | seekingalpha.com

iBio shares more than double in value after hours on new immuno-oncology target program

January 24, 2023 | marketwatch.com

Cancer Care Market is booming in near Future 2023-2028

January 13, 2023 | finanznachrichten.de

Nerviano Medical Sciences S.r.l.: Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset

January 12, 2023 | yahoo.com

Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset

January 5, 2023 | thestreet.com

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

November 26, 2022 | marketwatch.com

Cancer Care Market : Share, Industry Size, Opportunities, Analysis and Forecast to 2028 with Top Countries Data

November 12, 2022 | finance.yahoo.com

Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor

October 20, 2022 | finance.yahoo.com

Gadeta Appoints Scientific Advisory Board and Provides Business Update

September 27, 2022 | marketwatch.com

Global Cancer Care Market Size and Scope 2022 Research Report by Consumption, Revenue, Regions, Gross Margin and Forecast to 2026

September 24, 2022 | finanznachrichten.de

Celyad Oncology SA: Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

September 7, 2022 | finance.yahoo.com

Candel Therapeutics Announces Two Executive Leadership Appointments

See More Headlines

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ZIOP
CUSIP: 98973P10
CIK: 1107421
Web: www.ziopharm.com
Phone: (617) 259-1970
Fax: 617-241-2855
Employees: 105
Year Founded: 2005

Profitability

EPS (Most Recent Fiscal Year): ($0.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-79,980,000.00
Net Margins: N/A
Pretax Margin: -22,544.97%
Return on Equity: -92.84%
Return on Assets: -72.46%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 3.43
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.58 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 216,146,000
Free Float: 204,906,000
Market Cap: $187.12 million
Optionable: Optionable
Beta: 1.71

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Kevin S. Boyle
Chief Executive Officer & Director
Timothy M. Cunningham
Chief Financial Officer
Lynn M. Ferrucci
EVP-Human Resources, Administration & IT
Raffaele Baffa
Chief Medical Officer & Head-Research
Eleanor M. de Groot
General Manager-Cell Therapy & Executive VP

Key Competitors

View All Competitors

ZIOP Stock Analysis - Frequently Asked Questions

How were ZIOPHARM Oncology's earnings last quarter?: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter. During the same quarter in the prior year, the company posted ($0.10) EPS.
What other stocks do shareholders of ZIOPHARM Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

This page (NASDAQ:ZIOP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

ZIOP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ZIOP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info